RTP Mobile Logo
Select Publications

Ahn M et al. TATTON ph Ib expansion cohort: Osimertinib plus savolitinib for pts with EGFR-mutant MET-amplified NSCLC after progression on prior EGFR-TKI. Proc IASLC 2017;Abstract OA 09.03.

An open-label, multi-drug, biomarker-directed, multi-centre phase II umbrella study in patients with non-small cell lung cancer, who progressed on an anti-PD-1/PD-L1 containing therapy (HUDSON). NCT03334617

Antonia SJ et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018;379(24):2342-50. Abstract

Camidge DR et al. Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC. Proc ASCO 2018;Abstract 9043.

Cavanna L et al. Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis. Oncotarget 2019;10(2):209-15. Abstract

Chung HC et al. Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158. Proc ASCO 2018;Abstract 8506.

Dudnik E et al. BRAF mutant lung cancer: Programmed death ligand 1 expression, tumor mutational burden, microsatellite instability status, and response to immune check-point inhibitors. J Thorac Oncol 2018;13(8):1128-37. Abstract

Gandhi L et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med 2018;378(22):2078-92. Abstract

Garon EB et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial. Lancet 2014;384(9944):665-73. Abstract

Hellmann MD et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med 2018;378(22):2093-104. Abstract

Horn L et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 2018;379(23):2220-9. Abstract

Li B et al. Impact of smoking on efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer patients: A meta-analysis. Onco Targets Ther 2018;11:3691-6. Abstract

Lin JJ et al. Brigatinib in patients with alectinib-refractory ALK-positive non-small cell lung cancer: A retrospective study. J Thorac Oncol 2018;13(10):1530-8. Abstract

Lopes G et al. Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥1%: Open-label, phase 3 KEYNOTE-042 study. Proc ASCO 2018;Abstract LBA4.

Magnuson WJ et al. Management of brain metastases in tyrosine kinase inhibitor-naïve epidermal growth factor receptor-mutant non-small-cell lung cancer: A retrospective multi-institutional analysis. J Clin Oncol 2017;35(10):1070-7. Abstract

Paz-Ares LG et al. Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC). Proc ASCO 2018;Abstract 105.

Paz-Ares LG et al. Treatment outcomes by histology in REVEL: A randomized phase III trial of ramucirumab plus docetaxel for advanced non-small cell lung cancer. Lung Cancer 2017;112:126-33. Abstract

Ramalingam SS et al. Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J Clin Oncol 2018;36(9):841-9. Abstract

Ready N et al. First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): Outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers. J Clin Oncol 2019;37(12):992-1000. Abstract

Rizvi H et al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol 2018;36(7):633-41. Abstract

Shaw AT et al. Efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) and ALK kinase domain mutations. Proc AACR 2018;Abstract CT044.

Socinski MA et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 2018;378(24):2288-301. Abstract

Spigel DR et al. Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC). Proc ESMO 2017;Abstract 1297O.

Wang DY et al. Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. JAMA Oncol 2018;4(12):1721-8. Abstract